Genital and Perinatal Herpes Simplex Virus Infections

Sexually Transmitted Diseases

Volumn , Issue , 2013, Pages 273-313

  Stanberry, Lawrence R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882823762     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391059-2.00012-7     Document Type: Chapter

References (246)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329(5996):1168-1174.
2. Akhrameyeva N.V., Zhang P., Sugiyama N., Behar S.M., Yao F. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J. Virol. 2011, 85:5036-5047.
3. American College of Obstetricians and Gynecologists Perinatal herpes simplex virus infections. ACOG Technical Bulletin 122, ACOG, Washington DC 1988.
4. American College of Obstetrics and Gynecology Practice Bulletin No. 8, Management of herpes in pregnancy: 1999. Int. J. Gynaecol. Obstet. 2000, 68:165-173.
5. Arvin A.M., Whitley R.J., Gutierrez K.M. Herpes Simplex Virus Infections. Infectious Diseases of the Fetus and Newborn Infant 2006, 845-865. Elsevier Saunders, Philadelphia, PA. sixth ed. J.S. Remington, J.O. Klein, C.B. Wilson, C.J. Baker (Eds.).
6. Arvin A.M. The epidemiology of perinatal herpes simplex virus infections. Genital and Neonatal Herpes 1996, 179-192. John Wiley and Sons, Ltd., London. L.R. Stanberry (Ed.).
7. Ashley R., Militoni J., Lee F., Nahmias A., Corey L. Comparison of western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J. Clin. Micro. 1988, 26:662-667.
8. Ashley R.L., Corey L., Doles J., Wilson P., Remington M., Barnum G., Trethewey P. Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections. J. Infect. Dis. 1994, 170:20-26.
9. Awasthi S., Lubinski J.M., Shaw C.E., Barrett S.M., Cai M., Wang F., et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J. Virol. 2011 Oct, 85(20):10472-10486.
10. Baker D., Brown Z., Hollier L.M., Wendel G.D., Hulme L., Griffiths D.A., Mauskopf J. Cost-effectiveness of herpes simplex virus type 2 serologic testing and antiviral therapy in pregnancy. Am. J. Obstet. Gynecol. 2004, 191:2074-2084.
11. Baker D.A., Pressley A., Meek L., Figueroa R., Yates B., Dix L. HSV serologic testing for pregnant women: willingness to be tested and factors affecting testing. Infect. Dis. Obstet. Gynecol. 2011, 874820.
12. Banks T.A., Nair S., Rouse B.T. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. J. Virol. 1993, 67:613-616.
13. Bauer D., Tampé R. Herpes viral proteins blocking the transporter associated with antigen processing TAP-from genes to function and structure. Curr. Top. Microbiol. Immunol. 2002, 269:87-99.
14. Bauer G.R., Khobzi N., Coleman T.A. Herpes simplex virus type 2 seropositivity and relationship status among U.S. adults age 20 to 49: a population-based analysis. BMC Infect. Dis. 2010, 10:359.
15. Belshe R.B., Leone P.A., Bernstein D.I., et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 2012, 366:34-43.
16. Benedetti J., Corey L., Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med. 1994, 121:847-854.
17. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St-Pierre C., Shafran S.D., Leroux-Roels G., Van Herck K., Bollaerts A., Dubin G. GlaxoSmithKline Herpes Vaccine Study Group. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin. Infect. Dis. 2005, 40:1271-1281.
18. Bernstein D.I., Ashley R.L., Stanberry L.R., Myers M.G. Detection of asymptomatic initial HSV infection in animals previously immunized with subunit HSV glycoprotein vaccines. J. Clin. Microbiol. 1990, 28:11-15.
19. Bernstein D.I., Harrison C.J., Jenski L., Myers M.G., Stanberry L.R. Cell mediated immunological responses and recurrent genital herpes in the guinea pig: Effects of glycoprotein immunotherapy. J. Immunol. 1991, 146:3571-3577.
20. Bernstein D.I., Stanberry L.R., Harrison C.J., Kappes J.C., Myers M.G. Antibody response to herpes simplex virus glycoprotein D: Effects of acyclovir and relationship to recurrence. J. Infect. Dis. 1987, 156:423-429.
21. Bernstein D.I., Stanberry L.R. Herpes simplex virus vaccines - new developments. Vaccine 1999, 17:1681-1689.
22. Bernstein D.I., Tepe E.R., Mester J.C., Arnold R.L., Stanberry L.R., Higgins T. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Vaccine 1999, 17:1681-1689.
23. Biraro S., Mayaud P., Morrow R.A., Grosskurth H., Weiss H.A. Performance of commercial herpes simplex virus type-2 antibody tests using serum samples from sub-Saharan Africa: a systematic review and meta-analysis. Sex. Transm. Dis. 2011, 38:140-147.
24. Blaney J.E., Nobusawa E., Brehm M.A., Bonneau R.H., Mylin L.M., Fu T.M., Kawaoka Y., Tevethia S.S. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 1998, 72:9567-9574.
25. Blank H., Haines H.G. Experimental human reinfection with herpes simplex virus. J. Invest. Dermatol. 1973, 61:223-225.
26. Bochud P.Y., Magaret A.S., Koelle D.M., Aderem A., Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J. Infect. Dis. 2007, 196:505-509.
27. Bourne N., Bravo F.J., Francotte M., Bernstein D.I., Myers M.G., Slaoui M., Stanberry L.R. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 2003, 187:542-549.
28. Bourne N., Milligan G.N., Schleiss M.R., Bernstein D.I., Stanberry L.R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996, 14:1230-1234.
29. Bourne N., Milligan G.N., Stanberry L.R., Stegall R., Pyles R.B. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J. Infect. Dis. 2005, 192:2117-2123.
30. Boursnell M.E., Entwisle C., Blakeley D., Roberts C., Duncan I.A., Chisholm S.E., Martin G.M., Jennings R., Ni Challanain D., Sobek I., Inglis S.C., McLean C.S. A genetically inactivated herpes simplex virus type 2 [HSV-2] vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 1997, 175:16-25.
31. Brain R.T. Biological therapy in virus diseases. Br. J. Dermatol. Syph. 1936, 48:21-26.
32. Bravo F.J., Myers M.G., Stanberry L.R. Neonatal herpes simplex virus infection: pathogenesis and treatment in the guinea pig. J. Infect. Dis. 1994, 169:947-955.
33. Brown E.L., Morrow R., Krantz E.M., Arvin A.M., Prober C.G., Yasukawa L.L., Corey L., Wald A. Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am. J. Obstet. Gynecol. 2006, 195:115-120.
34. Brown Z.A., Benedetti J., Ashley R., Burchett S., Selke S., Berry S., Vontver L.A., Corey L. Neonatal herpes simplex virus infections in relation to asymptomatic maternal infection at the time of labor. N. Engl. J. Med. 1991, 324:1247-1252.
35. Brown Z.A., Kern E.R., Spruance S.L., Overall J.C. Clinical and virological course of herpes simplex genitalis. West. J. Med. 1979, 130:414-421.
36. Brown Z.A., Selke S., Zeh J., Kopelman J., Maslow A., Ashley R.L., Watts D.H., Berry S., Herd M., Corey L. The acquisition of herpes simplex during pregnancy. N. Engl. J. Med. 1997, 337:509-515.
37. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289:203-209.
38. Bussiere J.L., McCormick G.C., Green J.D. Preclinical safety assessment: considerations in vaccine development. Vaccine Design: The Subunit and Adjuvant Approach 1995, 61-80. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
39. Cameron D.W., Simonsen J.N., D'Costa L.J., Ronald A.R., Maitha G.M., Gakinya M.N., Cheang M., Ndinya-Achola J.O., Piot P., Brunham R.C. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989, ii:403-407.
40. Cappel R., Sprecher S., De Cuyper F., De Braekeleer J. Clinical efficacy of a herpes simplex subunit vaccine. J. Med. Virol. 1985, 16:137-145.
41. Cappel R., Sprecher S., de Cuyper F. Immune responses to DNA free herpes simplex proteins in man. Dev. Biol. Stand. 1982, 52:345-350.
42. Cappel R., Sprecher S., Rickaert F., de Cuyper F. Immune response to a DNA free herpes simplex vaccine in man. Arch. Virol. 1982, 73:61-67.
43. Carney O., Ross E., Bunker C., Ikkos G., Mindel A. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin. Med. 1994, 70:40-45.
44. Carney O., Ross E., Ikkos G., Mindel A. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin. Med. 1993, 69:457-459.
45. Cates W. After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet 2010, 376(9740):495-496.
46. Cattamanchi A., Posavad C.M., Wald A., Baine Y., Moses J., Higgins T.J., Ginsberg R., Ciccarelli R., Corey L., Koelle D.M. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin. Vaccine Immunol. 2008, 15:1638-1643.
47. Centers for Disease Control and Prevention (CDC) Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years - United States, 2005-2008. MMWR Morb. Mortal. Wkly. Rep. 2010, 59:456-459.
48. Centers for Disease Control and Prevention 2010 Sexually transmitted diseases treatment guidelines. Morbidity and Mortality Weekly Report 2010, 59. No. RR-12.
49. Christie S.N., McCaughey C., McBride M., Coyle P.V. Herpes simplex type 1 and genital herpes in Northern Ireland. Int. J. STD AIDS 1997, 8:68-70.
50. ®) in healthy young women administered twice daily for 14 days. PLoS One 2011 Jan 20, 6(1):e16258.
51. Conant M.A., Spicer D.W., Smith C.D. Herpes simplex virus transmission: condom studies. Sex. Transm. Dis. 1984, 11:94-95.
52. Corey L., Wald A. Genital Herpes. Sexually Transmitted Diseases 2007, 399-439. McGraw-Hill, Inc., New York, NY. fourth ed. K.K. Holmes, P.F. Sparling, W.E. Stamm, P. Piot, J.M. Wasserheit, L. Corey, M. Cohen (Eds.).
53. Corey L., Langenberg A.G., Ashley R., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999, 282:331-340.
54. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., Douglas J.M., Paavonen J., Morrow R.A., Beutner K.R., Stratchounsky L.S., Mertz G., Keene O.N., Watson H.A., Tait D., Vargas-Cortes M. Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 2004, 350:11-20.
55. Corey L., Wald A. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med. 2009, 361:1376-1385.
56. Corey L. Raising the consciousness for identifying and controlling viral STDs: Fears and frustrations. Sex. Transm. Dis. 1998, 25:58-69.
57. Cose S.C., Jones C.M., Wallace M.E., Heath W.R., Carbone F.R. Antigen-specific CD8+ T cell subset distribution in lymph nodes draining the site of herpes simplex virus infection. Eur. J. Immunol. 1997, 27:2310-2316.
58. Cunningham A.L., Taylor R., Taylor J., Marks C., Shaw J., Mindel A. Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. Sex. Transm. Infect. 2006, 82:164-168.
59. Da Costa X.J., Bourne N., Stanberry L.R., Knipe D.M. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997, 232:1-12.
60. Da Costa X.J., Morrison L.A., Knipe D.M. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 2001 Sep 30, 288(2):256-263.
61. Dasgupta G., Benmohamed L. Of mice and not humans: How reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?. Vaccine 2011, 29:5824-5836.
62. de Bruyn G., Vargas-Cortez M., Warren T., et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006, 24:914-920.
63. De Maria A., Tundo P., Romano A., Grima P. Anti-HSV-1 herpes vaccination by LUPIDON H: preliminary results. Adv. Exp. Med. Biol. 1995, 371B:1599-1600.
64. Dix R.D. Prospects for a vaccine against herpes simplex virus types 1 and 2. Prog. Med. Virol. 1987, 34:89-128.
65. Dong L., Li P., Oenema T., McClurkan C.L., Koelle D.M. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J. Immunol. 2010, 184:3063-3071.
66. Dudley K.L., Bourne N., Milligan G.N. Immune protection against HSV-2 in B-cell-deficient mice. Virology 2000, 270:454-463.
67. Dundarov S., Andonov P. Seventeen years of application of herpes vaccines in Bulgaria. Acta. Virol. 1994, 38:205-208.
68. Eberle R., Mou S.W., Zaia J.A. Polypeptide specificity of the early antibody response following primary and recurrent genital herpes simplex virus type 2 infections. J. Gen. Virol. 1984, 65:1839-1843.
69. Eberle R., Mou S.W., Zaia J.A. The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections. J. Med. Virol. 1985, 16:147-162.
70. Eberle R., Mou S.W. Relative titers of antibodies to individual polypeptide antigens of herpes simplex virus type 1 in human sera. J. Infect. Dis. 1983, 148:436-444.
71. Ekwo E., Wong Y.W., Myers M.G. Asymptomatic cervicovaginal shedding of herpes simplex virus. Am. J. Obstet. Gynecol. 1979, 134:102-103.
72. Erturk M., Phillpotts R.J., Welch M.J., Jennings R. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection. Vaccine 1991, 9:728-734.
73. Faber M.T., Nielsen A., Nygård M., Sparén P., Tryggvadottir L., Hansen B.T., et al. Genital Chlamydia, Genital Herpes, Trichomonas vaginalis and Gonorrhea Prevalence, and Risk Factors Among Nearly 70,000 Randomly Selected Women in 4 Nordic Countries. Sex. Transm. Dis. 2011, 38:727-734.
74. Farrell H.E., McLean C.S., Harley C., Efstathiou S., Inglis S., Minson A.C. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol. 1994, 68:927-932.
75. Ferrer R.M., Kraiselburd E.N., Kouri Y.H. Inapparent genital herpes simplex virus infection in women attending a venereal disease clinic. Sex. Transm. Dis. 1983, 10:91-92.
76. Fife K.H., Williams J.A., Thomas A.L., Ofner S., Katz B.P., Fortenberry J.D. Herpes Simplex Virus Type 2 Infection in Young Adult Women: Risk Factors for Infection and Frequency of Viral Shedding. Sex. Transm. Dis. 2010, 37:248-252.
77. Flagg E.W., Weinstock H. Incidence of neonatal herpes simplex virus infections in the United States, 2006. Pediatrics 2011, 127:e1-e8.
78. Fleming D.T., McQuillan G.M., Johnson R.E., Nahmias A.J., Aral S.O., Lee F.K., St.Louis M.E. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 1997, 337:1105-1111.
79. Frank S.B. Formolized herpes virus therapy and neutralizing substance in herpes simplex. J. Invest. Dermatol. 1938, 1:267-282.
80. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 1998, 177:1155-1161.
81. Gallichan W.S., Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995, 13:1589-1595.
82. Garcon N., Leroux-Roels G., Chen W- F. Vaccine adjuvants. Perspectives in Vaccinology: Understanding Modern Vaccines 2011, 89-113. Elsevier, London. N. Garçon, P.L. Stern, A.L. Cunningham, L.R. Stanberry (Eds.).
83. Gardella C., Brown Z. Prevention of neonatal herpes. BJOG. 2011, 18:187-192.
84. Garnett G.P., Dubin G., Slaoui M., Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex. Transm. Infect. 2004, 80:24-29.
85. Genocea, 2011. (accessed December 30, 2011). http://www.genocea.com/.
86. Glorioso J.C., Kees U., Kumel G., Kirchner H., Krammer P.H. Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J. Immunol. 1985, 135:575-582.
87. Gupta R., Warren T., Wald A. Genital herpes. Lancet 2007, 370(9605):2127-2137.
88. Gupta R., Wald A., Krantz E., Selke S., Warren T., Vargas-Cores M., Miller G., Corey L. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J. Infect. Dis. 2004, 190:1374-1381.
89. Gwanzura L., McFarland W., Alexander D., Burke R.L., Katzenstein D. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J. Infect. Dis. 1998, 177:481-484.
90. Haddad J., Langer B., Astruc D., Messer J., Lokiec F. Oral acyclovir and recurrent genital herpes during late pregnancy. Obstet. Gynecol. 1993, 82:102-104.
91. Halford W.P., Püschel R., Gershburg E., Wilber A., Gershburg S., Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 2011, 6(3):e17748.
92. Hall M.J., Katrak K. The quest for a herpes simplex virus vaccine: background and recent developments. Vaccine 1986, 4:138-150.
93. Handsfield H.H., Waldo A.B., Brown Z.A., Corey L., Drucker J.L., Ebel C.W., Leone P.A., Stanberry L.R., Whitley R.J. Neonatal herpes should be a reportable disease. Sex. Transm. Dis. 2005, 32:521-525.
94. Heineman T.C., Connelly B.L., Bourne N., Stanberry L.R., Cohen J.I. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J. Virol. 1995, 69:8109-8113.
95. Henocq E. Vaccin anti-herpetique. Rev. Med. (Paris) 1967, 8:695-708.
96. Hickling J.K., Chrisholm S.E., Duncan Taylor E.J., Boswell C., McLean C.S., Uttridge J., Roberts J.S.C., Tomasi A., Stanberry L., Bernstein D.I., Boursnell M.E.G., Inglis S.C. Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in phase I clinical trials in HSV-2 seropositive and seronegative volunteers May 1998, Abstracts of the 8th International Congress on Infectious Diseases, Boston, Massachusetts, Abstract 22.008, p. 89.
97. Hollier L.M., Wendel G.D. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst. Rev. 2008 Jan 23, (1):CD004946.
98. Hook E.W., Cannon R.O., Nahmias A.J., Lee F.F., Campbell C.H., Glasser D., Quinn T.C. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J. Infect. Dis. 1992, 165:251-255.
99. Hosken N., McGowan P., Meier A., Koelle D.M., Sleath P., Wagener F., et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 2006, 80:5509-5515.
100. Hughes H.P.A., Babiuk L.A. Potentiation of vaccines through effective adjuvant formulations and manipulation of the immune response. Modern Vaccinology 1994, 87-120. New York Plenum Medical Book Co. E. Kurstak (Ed.).
101. Jacobs R.F. Neonatal herpes simplex virus infections. Semin. Perinatol. 1998, 22:64-71.
102. Janier M., Scieux C., Meouchi R., et al. Virological, serological and epidemiological study of 255 consecutive cases of genital herpes in a sexually transmitted disease clinic of Paris (France): a prospective study. Int. J. STD AIDS 2006, 17:44-49.
103. Jawetz E., Allende M.F., Coleman V.R. Studies on herpes simplex virus. VI. Observations on patients with recurrent herpetic lesions injected with herpes viruses or their antigens. Am. J. Med. Sci. 1955, 229:477-485.
104. Johnson A.J., Chu C.F., Milligan G.N. Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J. Virol. 2008, 82:9678-9688.
105. Johnson R.M., Lancki D.W., Fitch F.W., Spear P.G. Herpes simplex virus glycoprotein D is recognized as antigen by CD4+ and CD8+ T lymphocytes from infected mice. J. Immunol. 1990, 145:702-710.
106. Karem K.L., Bowen J., Kuklin N., Rouse B.T. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J. Gen. Virol. 1997, 78:427-434.
107. Kask A.S., Chen X., Marshak J.O., Dong L., Saracino M., Chen D., Jarrahian C., Kendall M.A., Koelle D.M. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 2010, 28:7483-7491.
108. Kavaklova L., Dundarov S., Andonov P., Bakalov B., Dundarova D., Brodvarova I. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines. Acta. Virol. 1986, 30:402-410.
109. Keller M.J., Tuyama A., Carlucci M.J., Herold B.C. Topical microbicides for the prevention of genital herpes infection. J. Antimicrob. Chemother. 2005, 55:420-423.
110. Kern A.B., Schiff B.L. Vaccine therapy in recurrent herpes simplex. Arch. Dermatol. 1964, 89:844-845.
111. Khodai T., Chappell D., Christy C., Cockle P., Eyles J., Hammond D., et al. Single and combination HSV-2 glycoprotein vaccines adjuvanted with CPG or MPL exhibit differential immunity in animal models, but this is not correlated to protection. Clin. Vaccine. Immunol. 2011, 18(10):1702-1709.
112. Kim M., Taylor J., Sidney J., Mikloska Z., Bodsworth N., Lagios K., Dunckley H., Byth-Wilson K., Denis M., Finlayson R., Khanna R., Sette A., Cunningham A.L. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J. Immunol. 2008, 181:6604-6615.
113. Knipe D.M. Cell growth transformation by herpes simplex virus. Prog. Med. Virol. 1982, 28:114-144.
114. Koelle D.M., Corey L., Burke R.L., Eisenberg R.J., Cohen G.H., Pichyangkura R., Triezenberg S.J. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 1994, 68:2803-2810.
115. Koelle D.M., Frank J.M., Johnson M.L., Kwok W.W. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 1998, 72:7476-7483.
116. Koelle D.M., Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 2000, 45(Suppl. T3):1-8.
117. Kohl S. Neonatal herpes simplex virus infection. Clin. Perinatol. 1997, 24:129-150.
118. Kortekangas-Savolainen O., Vuorinen T. Trends in herpes simplex virus type 1 and 2 infections among patients diagnosed with genital herpes in a Finnish sexually transmitted disease clinic, 1994-2002. Sex. Transm. Dis. 2007, 34:37-40.
119. Koutsky L.A., Stevens C.E., Holmes K.K., et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N. Engl. J. Med. 1992, 326:1533-1539.
120. Kropp R.Y., Wong T., Cormier L., Ringrose A., Burton S., Embree J.E., et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006, 117:1955-1962.
121. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 1997, 71:3138-3145.
122. Kutinova L., Slichtova V., Vonka V. Subviral herpes simplex vaccine. Dev. Biol. Stand. 1982, 52:313-319.
123. Kwant-Mitchell A., Ashkar A.A., Rosenthal K.L. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J. Virol. 2009, 83:10664-10676.
124. Laing K.J., Magaret A.S., Mueller D.E., Zhao L., Johnston C., De Rosa S.C., Koelle D.M., Wald A., Corey L. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J. Clin. Immunol. 2010, 30:703-722.
125. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., Corey L. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann. Intern. Med. 1995, 122:889-898.
126. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 1996, 8:348-354.
127. LaRossa D., Hamilton R. Herpes simplex virus infections of the digits. Arch. Surg. 1971, 102:600-603.
128. Leone P., Warren T., Hamed K., Fife K., Wald A. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex. Transm. Dis. 2007, 34:900-907.
129. Leroux-Roels G, Moreau E, Desombre I., 1994. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2) candidate vaccine with MPL. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, p. 205 (abstract H57).
130. Lewis L.M., Bernstein D.I., Rosenthal S.L., Stanberry L.R. Seroprevalence of herpes simplex virus type 2 in African-American college women. J. National Med. Assoc. 1999, 91:210-212.
131. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 2011, 239:62-84.
132. Longo D., Koehn K. Psychosocial factors and recurrent genital herpes: a review of prediction and psychiatric treatment studies. Int. J. Psychiatry Med. 1993, 23:99-117.
133. Malvy D., Halioua B., Lançon F., Rezvani A., Bertrais S., Chanzy B., Daniloski M., Ezzedine K., Malkin J.E., et al. Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study. Sex. Transm. Dis. 2005, 32:499-505.
134. Manickan E., Francotte M., Kuklin D., Dewerchin M., Molitor C., Gheysen D., Slaoui M., Rouse B.T. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J. Virol. 1995, 69:4711-4716.
135. Manickan E., Rouse R.J., Yu Z., Wire W.S., Rouse B.T. Genetic immunization against herpes simplex virus is mediated by CD4+ T lymphocytes. J. Immunol. 1995, 155:259-265.
136. Manning W.C., Paliard X., Zhou S., Pat Bland M., Lee A.Y., Hong K., Walker C.M., Escobedo C.M., Dwarki V. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoprotein B and D. J. Virol. 1997, 71:7960-7962.
137. Martin E.T., Krantz E., Gottlieb S.L., Magaret A.S., Langenberg A., Stanberry L., et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch. Intern. Med. 2009, 169:1233-1240.
138. Martin S., Courtney R.L., Fowler G., Rouse B.T. Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize non-structural proteins. J. Virol. 1988, 62:2265-2273.
139. Meignier B., Longnecker R., Roizman R. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 1988, 58:602-614.
140. Meignier B. Vaccination against herpes simplex virus infections. The Herpesviruses 1985, vol. 4,:256-312. Plenum, New York. B. Roizman, C. Lopez (Eds.).
141. Mertz G.J., Ashley R., Burke R.L., Benedetti J., Critchlow C., Jones C.C., Corey L. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 1990, 161:653-660.
142. Mertz G.J., Schmidt O., Jourden J.L., Guinan M.E., Remington M.L., Fahnlander A., Winter C., Holmes K.K., Corey L. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Transm. Dis. 1985, 12:33-39.
143. Meseda C.A., Elkins K.L., Merchlinsky M.J., Weir J.P. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 2002, 186:1065-1073.
144. Mester J.C., Milligan G.N., Bernstein D.I. The immunobiology of herpes simplex virus. Genital and Neonatal Herpes 1996, 49-92. John Wiley and Sons, Chichester. L.R. Stanberry (Ed.).
145. Mikloska Z., Cunningham A.L. Herpes simplex virus type 1 glycoproteins gB, gC, and gD are major targets for CD4 lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J. Gen. Virol. 1998, 79:353-361.
146. Milligan G.N., Bernstein D.I., Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 1998, 160:6093-6100.
147. Milligan G.N., Bernstein D.I. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology 1995, 206:234-241.
148. Mindel A., Marks C. Psychological symptoms associated with genital herpes virus infections: Epidemiology and approaches to management. CNS Drugs 2005, 19:303-312.
149. Mindel A., Taylor J. Debate: the argument against. Should every STD clinic patient be considered for type-specific serological screening for HSV?. Herpes 2002, 9:35-37.
150. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand. J. Infect. Dis. Suppl. 1996, 100:27-32.
151. Mo A., Musselli C., Chen H., Pappas J., et al. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 2011, 29:8530-8541.
152. Morello C.S., Levinson M.S., Kraynyak K.A., Spector D.H. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J. Virol. 2011, 85:3461-3472.
153. Morris G.C., Lacey C.J. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr. Opin. Infect. Dis. 2010, 23:57-63.
154. Morrison L.A., Knipe D.M. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology 1996, 220:402-413.
155. Nahmias A.J., Josey W.E., Naib Z.M., Freeman M.G., Fernandez R.J., Wheeler J.H. Perinatal risk associated with maternal genital herpes simplex virus infection. Am. J. Obstet. Gynecol. 1971, 110:825-837.
156. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J. Virol. 2006, 80:4447-4457.
157. Nelson M.H., Bird M.D., Chu C.F., Johnson A.J., Friedrich B.M., Allman W.R., Milligan G.N. Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions. J. Reprod. Immunol. 2011, 89:10-17.
158. Paladino P., Mossman K.L. Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J. Interferon Cytokine Res. 2009, 29:599-607.
159. Parr E.L., Bozzola J.J., Parr M.B. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus. J. Reprod. Immunol. 1998, 38:15-30.
160. Patel R., Stanberry L., Whitley R.J. Review of recent HSV recurrent-infection treatment studies. Herpes 2007, 14(1):23-26.
161. Phillpotts R.J., Welch M.J., Ridgeway P.H., Walkland A.C., Melling J. A test for the relative potency of herpes simplex virus vaccines based upon the female guinea-pig model of HSV 2 genital infection. J. Biol. Stand. 1988, 16:109-118.
162. Posavad C.M., Remington M., Mueller D.E., et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J. Immunol. 2010, 184:3250-3259.
163. Prober C.G. Clinical features and diagnostic evaluation of perinatal herpes simplex virus infections. Genital and Neonatal Herpes 1996, 193-208. John Wiley and Sons, Ltd., London. L.R. Stanberry (Ed.).
164. Quenelle D.C., Collins D.J., Rice T.L., Prichard M.N., Marciani D.J., Kern E.R. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. Antiviral Res. 2008, 80:223-224.
165. Randolph A.G., Washington A.E., Prober C.G. Caesarean delivery for women presenting with genital herpes lesions. Efficacy, risks, and costs. JAMA 1993, 270:77-82.
166. Rattray M.C., Corey L., Reeves W.C. Recurrent genital herpes among women: symptomatic versus asymptomatic shedding. Br. J. Vener. Dis. 1978, 54:262-265.
167. Read J.S., Cannon M.J., Stanberry L.R., Schuval S. Prevention of mother-to-child transmission of viral infections. Curr. Probl. Pediatr. Adolesc. Health Care 2008, 38:274-297.
168. Reeves W.C., Corey L., Adams H.G., Vontver L.A., Holmes K.K. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N. Engl. J. Med. 1981, 305:315-319.
169. Reeves W.C., Corey L., Adams H.G. Risk of recurrence after first episodes of genital herpes: relation of HSV type and antibody response. N. Engl. J. Med. 1981, 305:315-319.
170. Reszka N.J., Dudek T., Knipe D.M. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010, 28:2754-2762.
171. Richards J., Scholes D., Caka S., Drolette L., Magaret A.M., Yarbro P., et al. HSV-2 serologic testing in an HMO population: uptake and psychosocial sequelae. Sex. Transm. Dis. 2007, 34:718-725.
172. Roberts C. Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Herpes 2005, 12:10-14.
173. Roberts J.S.C., Uttridge J.A., Hickling J.K., Loudon P.T., McLean C.S., Boursnell M.E.G., Inglis S.C., Belli J.A., Bernstein D.I., Stanberry L. Safety, tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase I clinical trials in HSV-2 seropositive and seronegative volunteers May 1998, Abstracts of the 8th International Congress on Infectious Diseases, Boston, Massachusetts,, Abstract 22.009, p. 89.
174. Robinson A.J., Nicholson B.H., Lyttle D.J. Engineered viruses and vaccines. Synthetic Vaccines 1994, 331-375. B.H. Nicholson (Ed.).
175. Rosenthal S., Zimet G., Leichliter J., Stanberry L., Fife K., Tu W., Bernstein D. The psychosocial impact of serological diagnosis of asymptomatic Herpes Simplex Virus type 2 infection. Sex. Transm. Infect. 2006, 82:154-157.
176. Rosenthal S.L., Cohen S.S., Stanberry L.R. Topical microbicides. Current status and research considerations for adolescent girls. Sex. Transm. Dis. 1998, 25:368-377.
177. Rosenthal S.L., Stanberry L.R., Biro F.M., Slaoui M., Francotte M., Koutsoukos M., Hayes M., Bernstein D.I. Seroprevalence of herpes simplex virus type 1 and type 2 and cytomegalovirus in adolescents. Clin. Infect. Dis. 1997, 24:135-139.
178. Rupp R., Rosenthal S.L., Stanberry L.R. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomedicine 2007, 2:561-566.
179. Russell M.W., Mestecky J. Tolerance and protection against infection in the genital tract. Immunol. Invest. 2010, 39:500-525.
180. Sacks S.L., Hughes A., Rennie B., Boon R. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: a randomized, double-blind, double dummy, parallel group, placebo-controlled trial. In: Programs and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997.
181. Sacks S.L., Shafran S.D. BID famciclovir suppression of asymptomatic genital herpes simplex virus shedding in men. In: Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, 1998.
182. Salvucci L.A., Bonneau R.H., Tevethia S.S. Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for the recognition by HSV type 1-specific cytotoxic T lymphocytes. J. Virol. 1995, 69:1122-1131.
183. Schiffer J.T., Abu-Raddad L., Mark K.E., Zhu J., Selke S., Koelle D.M., Wald A., Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc. Natl. Acad. Sci. U S A 2010, 107:18973-18978.
184. Schmidt O.W., Fife K.H., Corey L. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J. Infect. Dis. 1994, 149:645-646.
185. Sin J.I., Kim J.J., Arnold R.L., et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J. Immunol. 1999, 162:2912-2921.
186. Skinner G.R., Fink C., Melling J., Wiblin C., Thornton B., Hallworth J., Gardner W., McLeish P., Hartley C., Buchan A. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med. Microbiol. Immunol. (Berl) 1992, 180:305-320.
187. Skinner G.R., Fink C.G., Cowan M., Buchan A., Fuller A., Hartley C.E., Durham J., Wiblin C., Melling J. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med. Microbiol. Immunol. (Berl) 1987, 176:161-168.
188. Skinner G.R., Williams D.R., Buchan A., Whitney J., Harding M., Bodfish K. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection. Med. Microbiol. Immunol. 1978, 166:119-132.
189. Smith J.S., Bailey R.C., Westreich D.J., Maclean I., Agot K., Ndinya-Achola J.O., et al. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing. Sex. Transm. Infect. 2009, 85:92-96.
190. Smith J.S., Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 2002, 186(Suppl. 1):S3-28.
191. Spector F.C., Kern E.R., Palmer J., Kaiwar R., Cha T.A., Brown P., Spaete R.R. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Infect. Dis. 1998, 177:1143-1154.
192. St Leger A.J., Peters B., Sidney J., Sette A., Hendricks R.L. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J. Immunol. 2011, 186:3927-3933.
193. Stanberry L., Cunningham A., Mertz G., Mindel A., Peters B., Reitano M., et al. New Developments in the Epidemiology, Natural History and Management of Genital Herpes. Antiviral Research 1999, 42:1-14.
194. Stanberry L., Cunningham A., Mindel A., Scott L., Spruance S., Aoki F., Lacey C. Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. 2000, 30:549-566.
195. Stanberry L., Handsfield H., Sacks S., Peters B., Chinn C. The health care costs of genital herpes in the United States - a pharmacoeconomic model. Antiviral Res. 1999, 41:A58.
196. Stanberry L.R., Barrett A.B.T. Vaccine Development Pathway. Vaccines for Biodefense and Emerging and Neglected Diseases 2009, 45-54. Elsevier, London. A.D.T. Barrett, L.R. Stanberry (Eds.).
197. Stanberry L.R., Bernstein D.I., Burke R.L., Pachl C., Myers M.G. Recombinant herpes simplex virus glycoproteins: Protection against initial and recurrent genital herpes. J. Infect. Dis. 1987, 155:914-920.
198. Stanberry L.R., Bernstein D.I., Kit S., Myers M.G. Genital reinfection after recovery from initial herpes simplex virus type 2 genital infection in guinea pigs. J. Infect. Dis. 1986, 153:1055-1061.
199. Stanberry L.R., Myers M.G., Stephanopoulos D.I., Burke R.L. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: Factors influencing efficacy. J. Med. Virol. 1989, 70:3177-3185.
200. Stanberry L.R., Rosenthal S.L., Mills L., Succop P.A., Biro F.M., Morrow R.A., Bernstein D.I. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin. Infect. Dis. 2004, 39:1433-1438.
201. Stanberry L.R., Rosenthal S.L. Epidemiology of herpes simplex virus infections in adolescents. HERPES 1999, 6:12-15.
202. Stanberry L.R., Spruance S.L., Cunningham A.L., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002, 347:1652-1661.
203. Stanberry L.R. Herpes simplex virus vaccine evaluation in animals: the guinea pig model. Rev. Infect. Dis. 1991, 13(Suppl. 11):S920-S923.
204. Stanberry L.R. Herpes simplex virus vaccines as immunotherapeutic agents. Trends in Microbiology 1995, 3:244-247.
205. Stanberry L.R. Herpes simplex virus vaccines. Semin. Pediatr. Infect. Dis. 1991, 2:178-185.
206. Stanberry L.R. The pathogenesis of herpes simplex virus infections. Genital and Neonatal Herpes 1996, 31-48. John Wiley and Sons, Chichester. L.R. Stanberry (Ed.).
207. Stone K.M., Brooks C.A., Guinan M.E., Alexander E.R. National surveillance for neonatal herpes simplex virus infections. Sex. Transm. Dis. 1989, 16:152-156.
208. Straus S.E., Corey L., Burke R.L., et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343(8911):1460-1463.
209. Sucato G., Wald A., Wakabayashi E., Vieira J., Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J. Infect. Dis. 1998, 177:1069-1072.
210. Sundaram S.S., Alderson S., Patel R. HSV-1 genital infection rare in men over the age of 35 years. Int. J. STD AIDS 2009, 20:68.
211. Templeton D.J., Jin F., Prestage G.P., Donovan B., Imrie J.C., Kippax S.C., et al. Circumcision and risk of sexually transmissible infections in a community-based cohort of HIV-negative homosexual men in Sydney, Australia. J. Infect. Dis. 2009, 200:1813-1819.
212. Thompson C., Whitley R. Neonatal herpes simplex virus infections: where are we now?. Exp. Med. Biol. 2011, 697:221-230.
213. Tigges M.A., Koelle D., Hartog K., Sekulovich R.E., Corey L., Burke R.L. Human CD8+ herpes simplex virus specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J. Virol. 1992, 66:1622.
214. Tirabassi R.S., Ace C.I., Levchenko T., Torchilin V.P., Selin L.K., Nie S., Guberski D.L., Yang K. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 2011, 29:1090-1098.
215. Tizard M.L., Chan W.L. Differential T cell response induced by certain recombinant oligopeptides of herpes simplex virus glycoprotein B in mice. J. Gen. Virol. 1997, 78:1625-1632.
216. Tookey P., Peckham C.S. Neonatal herpes simplex virus infection in the British Isles. Paediatr. Perinat. Epidemiol. 1996 1996, 10:432-442.
217. Tronstein E., Johnston C., Huang M.L., Selke S., Magaret A., Warren T., Corey L., Wald A. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011, 305:1441-1449.
218. Turner K.R., Wong E.H., Kent C.K., Klausner J.D. Serologic herpes testing in the real world: validation of new type-specific serologic herpes simplex virus tests in a public health laboratory. Sex. Transm. Dis. 2002, 29:422-425.
219. Vandevenne P., Sadzot-Delvaux C., Piette J. Innate immune response and viral interference strategies developed by human herpesviruses. Biochem. Pharmacol. 2010, 80:1955-1972.
220. Wald A., Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin. Infect. Dis. 2002, 35(Suppl. 2):S173-S182.
221. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital HSV-2 shedding in immunocompetent women. J. Clin. Invest. 1997, 99:1092-1097.
222. Wald A., Corey L. Antiviral therapies for long-term suppression of genital herpes. JAMA 1999, 281:1169-1170.
223. Wald A., Corey L. The clinical features and diagnostic evaluation of genital herpes. Genital and Neonatal Herpes 1996, 109-138. John Wiley and Sons, Chichester. L.R. Stanberry (Ed.).
224. Wald A., Koelle D.M., Fife K., et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011, 29:8520-8529.
225. Wald A., Krantz E., Selke S., Lairson E., Morrow R.A., Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J. Infect. Dis. 2006, 194:42-52.
226. Wald A., Langenberg A.G., Krantz E., Douglas J.M., Handsfield H.H., DiCarlo R.P., et al. The relationship between condom use and herpes simplex virus acquisition. Ann. Intern. Med. 2005, 143:707-713.
227. Wald A., Selke S., Warren T., Aoki F.Y., Sacks S., Diaz-Mitoma F., Corey L. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex. Transm. Dis. 2006, 33:529-533.
228. Wald A., Zeh J., Barnum G., Davis L.G., Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 1996, 124:8-15.
229. Wald A., Zeh J., Barnum G., Davis L.G., Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 1996, 124:8-15.
230. Wald A., Zeh J., Selke S., Ashley R.L., Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. 1995, 333:770-775.
231. Wang X., Xie G., Liao J., Yin D., Guan W., Pan M., Li J., Li Y. Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice. Virol. J. May 16 2011, 8:232.
232. Watson R.J., Enquist L.W. Genetically engineered herpes simplex virus vaccines. Prog. Med. Virol. 1985, 31:84-108.
233. Whitley R., Arvin A., Prober C., Burchett S., Corey L., Powell D., Plotkin S., Starr S., Alford C., Connor J. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N. Engl. J. Med. 1991, 324:444-449.
234. Whitley R.J., Corey L., Arvin A., Lakeman F.D., Sumaya C.V., Wright P.F., Dunkle L.M., Steele R.W., Soong S.J., Nahmias A.J. Changing presentation of herpes simplex virus infection in neonates. J. Infect. Dis. 1988, 158:109-116.
235. Whitley R.J., Nahmias A.J., Visintine A.M., Fleming C.L., Alford C.A. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 1980, 66:489-494.
236. Whitley R.J., Roizman B. Herpes simplex virus infections. Lancet 2001, 357(9267):1513-1518.
237. Whitley R.J. Herpes simplex vaccines. New Generation Vaccines 1997, 727-748. Marcel Dekker, Inc, New York. second ed. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
238. Williams J.R., Jordan J.C., Davis E.A., Garnett G.P. Suppressive valacyclovir therapy: impact on the population spread of HSV-2 infection. Sex. Transm. Dis. 2007 Mar, 34(3):123-131.
239. Wu W., Huang L., Mendez S. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur. J. Immunol. 2010, 40:2517-2527.
240. Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
241. Yeager A.S., Arvin A.M., Urbani L.J., Kemp J.A. The relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect. Immun. 1980, 29:532-538.
242. Yeager A.S., Arvin A.M., Urbani L.J., Kemp J.A. Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect. Immun. 1980, 29:532-538.
243. Zhang X., Chentoufi A.A., Dasgupta G., et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal. Immunol. 2009, 2:129-143.
244. Zhu Q., Thomson C.W., Rosenthal K.L., McDermott M.R., Collins S.M., Gauldie J. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal. Immunol. 2008, 1:78-88.
245. Zimet G.D., Rosenthal S.L., Fortenberry J.D., Brady R.C., Tu W., Wu J., et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex. Transm. Dis. 2004, 31:665-669.
246. Zweerink H.J., Corey L. Virus-specific antibodies from in sera from patients with genital herpes simplex virus infection. Infect. Immun. 1982, 37:413-421.